title: Bone formation of block and particulated biphasic calcium phosphate lyophilized with Escherichia coli-derived recombinant human bone morphogenetic protein 2 in rat calvarial defects.
abstract: The objective of this study was to evaluate bone formation in rat calvarial defects after surgical implantation of block or particulated biphasic calcium phosphate (BCP) lyophilized with Escherichia coli-derived recombinant human bone morphogenetic protein 2 (ErhBMP-2). Critical-size calvarial osteotomy defects were created in 5 groups of Sprague-Dawley rats. Each group received one of the following: 1) sham surgery control; 2) biphasic calcium phosphate particles (CPP); 3) biphasic calcium phosphate block (CPB); 4) ErhBMP-2-coated CPP; or 5) ErhBMP-2-coated CPB. ErhBMP was coated on BCP by a stepwise lyophilizing protocol. The new bone formation was significantly greater in ErhBMP-2-treated groups compared with the untreated group. In particular, the ErhBMP-2/CPB group showed stability of augmented areas during the period of healing, due to relevant space-providing capacity. Thus, it can be concluded that CPP and CPB lyophilized with ErhBMP-2 enhance the formation of new bone, and CPB appears to be a suitable carrier for ErhBMP-2 in which a 3-dimensional structural integrity is an important consideration factor.
authors.affiliation: Research Institute for Periodontal Regeneration, Department of Periodontology, College of Dentistry, Yonsei University, Seodaemun-gu, Seoul, South Korea.
authors.forename: Jin-Woo
authors.initials: JW
authors.lastname: Kim
authors.forename: Kyung-Hee
authors.initials: KH
authors.lastname: Choi
authors.forename: Jeong-Ho
authors.initials: JH
authors.lastname: Yun
authors.forename: Ui-Won
authors.initials: UW
authors.lastname: Jung
authors.forename: Chang-Sung
authors.initials: CS
authors.lastname: Kim
authors.forename: Seong-Ho
authors.initials: SH
authors.lastname: Choi
authors.forename: Kyoo-Sung
authors.initials: KS
authors.lastname: Cho
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage* / Q000096:biosynthesis; D001861:Bone Regeneration / Q000187:drug effects* / Q000502:physiology; D018786:Bone Substitutes / Q000008:administration & dosage* / Q000737:chemistry; D020099:Coated Materials, Biocompatible / Q000008:administration & dosage* / Q000737:chemistry; D004337:Drug Carriers; D004926:Escherichia coli; D005612:Freeze Drying; D006801:Humans; D006882:Hydroxyapatites / Q000008:administration & dosage* / Q000737:chemistry; D008297:Male; D016348:Osseointegration / Q000187:drug effects / Q000502:physiology; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology; D010316:Particle Size; D015202:Protein Engineering / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000096:biosynthesis; D012886:Skull / Q000033:anatomy & histology / Q000187:drug effects / Q000601:surgery; D018709:Statistics, Nonparametric
chemical_list: C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D018786:Bone Substitutes; D020099:Coated Materials, Biocompatible; D004337:Drug Carriers; D006882:Hydroxyapatites; D011994:Recombinant Proteins; C074950:hydroxyapatite-beta tricalcium phosphate